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Abstract: The neurohypophyseal hormones, arginine vasopressin and corticotropin-releasing hormone (CRH), play a crucial 
role in the physiological and behavioral response to various kinds of stresses. Both neuropeptides activate the hypophysial-
pituitary-adrenal (HPA) axis, which is a central mediator of the stress response in the body. Conversely, they receive the 
negative regulation by glucocorticoid, which is an end product of the HPA axis. Vasopressin and CRH are closely linked to 
immune response; they also interact with pro-inﬂ  ammatory cytokines. Moreover, as for vasopressin, it has another important 
role, which is the regulation of water balance through its potent antidiuretic effect. Hence, it is conceivable that vasopressin 
and CRH mediate the homeostatic responses for survival and protect organisms from the external world.
A tight and elaborate regulation system of the vasopressin and CRH gene is required for the rapid and ﬂ  exible response to 
the alteration of the surrounding environments. Several important regulatory elements have been identiﬁ  ed in the proximal 
promoter region in the vasopressin and CRH gene. Many transcription factors and intracellular signaling cascades are 
involved in the complicated gene regulation system. This review focuses on the current status of the basic research of vaso-
pressin and CRH. In addition to the numerous known facts about their divergent physiological roles, the recent topics of 
promoter analyses will be discussed.
Introduction
In a severe environment, all organisms are constantly exposed to a wide variety of stresses, which 
sometimes even threaten their lives. Therefore, the acquisition of the ability to adapt to the environ-
mental changes probably gives them a great advantage for survival. The way in which adaptation occurs 
can be divided into some different types, such as physiological or behavioral response. The former 
includes an autonomic response such as fluid balance, vasoregulation, and energy homeostasis, most 
of which are biologically fundamental responses for the maintenance of the internal milieu. The immune 
response as a defense system may also be added here. The latter, a behavioral response to the external 
world, often becomes a basic strategy to win the struggle for existence. It includes fight and flight, eat-
ing and drinking, memory and learning, or emotional reactions such as fear and anxiety. For this purpose, 
whatever the response, the construction of an acute and accurate “cell-to-cell” or “organ-to-organ” 
communication system is required. Indeed, the highly-developed signal transduction system in the body 
is considerably orchestrated by the endocrine system.
The concept of stress was first advocated by Hans Selye (Selye, 1936; Selye, 1946). He noticed the 
importance of the adrenal cortex in the stress response from the observation that it was significantly 
enlarged under the stressful condition. Subsequently, numerous works have provided us with extended 
knowledge about the profound relationship between stress and the endocrine system (Besedovsky and 
del Rey, 1996; Turnbull and Rivier, 1999). In vertebrates, after stress is sensed by the peripheral organs, 
much information is gathered to the hypothalamus in the brain, and then many neuropeptides and neu-
rotransmitters begin to make appropriate and flexible responses in accordance with environmental 
changes. In this neuroendocrine response to the external world, in particular, hypothalamic vasopressin 
and corticotropin-releasing hormone (CRH) play a central role. Both neuropeptides are essential to 
keeping the life homeostasis.
Vasopressin is known as an antidiuretic hormone regulating water balance. The principal role of 
vasopressin is the maintenance of the plasma osmolality (≈285mOsm/H2O) by controlling water reab-
sorption in the kidney (Robertson, 1976; Schrier et al. 1979; Burbach et al. 2001). However, vasopressin 72
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possesses more divergent physiological actions, 
such as vasoconstriction and interaction with anti-
inflammatory mediators. On the other hand, CRH 
stimulates the rapid release of adrenocorticotropic 
hormone (ACTH) from the anterior pituitary 
(Rivier and Plotsky, 1986; Orth, 1992). Then, 
ACTH stimulates the glucocorticoid synthesis and 
secretion from the adrenal cortex. Glucocorticoid 
exerts a pleiotropic effect on energy metabolism, 
vasoregulation, and the immune system (Munck 
et al. 1984; Sapolsky et al. 2000; Buckingham, 
2006). Therefore, CRH is thought to act as an 
upstream regulator of this important cascade, the 
hypophysial-pituitary-adrenal (HPA) axis (Bale 
and Vale, 2004; Majzoub, 2006). Of particular 
interest is the fact that vasopressin enhances this 
stimulatory effect of CRH on ACTH secretion 
(DeBold et al. 1984; Antoni, 1993). In addition to 
the HPA axis activation, CRH directly regulates 
the feeding behavior and the emotional reaction 
in the brain: CRH induces the anorexigenic and 
anxiogenic reaction. Food intake is rapidly reduced 
(within 30min) after the central administration of 
CRH in rodents (Arase et al. 1988). This acute 
anorexigenic effect of a single injection does not 
persist for a long duration; however, the continuous 
infusion of CRH promotes body weight loss. CRH 
is also distributed in the extra-hypothalamic region 
including the amygdala and the bed nucleus of the 
stria terminalis (BNST), both of which are closely 
associated with fear and anxiety (Walker et al. 
2003), suggesting that CRH mediates the behavior 
in unfamiliar surroundings (Merali et al. 2004; 
Bale and Vale, 2004). On the other hand, the dys-
regulation of CRH in these regions probably causes 
depression or mood disorders (Stenzel-Poore et al. 
1994; Risbrough and Stein, 2006).
Thus, vasopressin and CRH are involved in the 
adaptation to the internal or external stress condi-
tion. Then, how is the gene expression of vasopres-
sin and CRH controlled, in response to this broad 
range of stresses? There are common transcription 
factors and intracellular signaling pathways for the 
strict gene regulation of both neuropeptides. This 
paper focuses on the current status of the basic 
research regarding the physiological role and the 
gene regulation system of these neuropeptides.
Structure
Vasopressin is a representative posterior pituitary 
hormone which was first discovered by du Vigneaud 
and his co-workers in the 1950s (Popenoe and du 
Vigneaud, 1954). The human vasopressin gene is 
composed of three exons and two introns, and is 
encoded in chromosome 20 (Ivell and Richter, 
1986). The structures of vasopressin and oxytocin, 
another posterior pituitary hormone, resemble each 
other. Interestingly, the vasopressin-coding region 
is at a distance of 12 kbp from that of the oxytocin 
gene in the opposite direction in the same 
chromosome, strongly suggesting that oxytocin is 
a duplicated gene of vasopressin.
Like many other neuropeptides, the bioactive 
form of vasopressin is generated from a large precur-
sor, preprovasopressin (Burbach et al. 2001). After 
the removal of the signal peptide, provasopressin is 
further processed into the three end products, neu-
rophysin II, glycoprotein, and mature vasopressin 
by intracellular processing. The bioactive vasopres-
sin has a cyclic structure due to an intramolecular 
disulfide bond between two cysteines. Neurophysin 
II is a unique cystein-rich polypeptide, known as an 
important carrier protein which supports the axonal 
transport of vasopressin in the vasopressinergic 
neurons (Gainer et al. 1977). On the other hand, the 
role of glycoprotein still remains unclear.
CRH is a 41-amino-acid neuropeptide which 
was first isolated from sheep hypothalamus (Vale 
et al. 1981). The human CRH gene is composed 
of two exons and one intron, encoded in chromo-
some 8. The CRH coding region starts in exon2 
and first of all, preproCRH is synthesized. As with 
vasopressin, after the removal of the signal peptide, 
the mature CRH peptide is generated by further 
processing of proCRH and N-terminal amidation. 
To date, CRH is known to belong to the CRH 
peptide family, along with urocortin1 (Ucn1) 
(Vaughan et al. 1995), Ucn2 (Reyes et al. 2001), 
and Ucn3 (Lewis et al. 2001). Ucns were originally 
identified as other ligands of CRH receptors. 
Mouse Ucn1 is approximately 45% identical to 
CRH (Vaughan et al. 1995), whereas mouse Ucn2 
shares 34% and 42% amino acid homology with 
rat CRH and rat Ucn1, respectively (Reyes et al. 
2001). On the other hand, Ucn3 is more distantly 
related to Ucn1 and CRH: mouse Ucn3 is 18% 
identical to mouse Ucn1, 40% to mouse Ucn2, and 
26% to rat CRH (Lewis et al. 2001).
Distribution and Receptors
The tissue distribution of the vasopressin gene is 
almost limited to the central nervous system, with 73
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a few exceptions. Vasopressin is mainly located in 
the magnocellular neurons of the supraoptic 
nucleus (SON), magnocellular and parvocellular 
parts of the paraventricular nucleus (PVN), and 
suprachiasmatic nucleus (SCN) of the hypothala-
mus. Vasopressin-positive neurons are also recog-
nized in the forebrain area, such as BNST and the 
medial amygdaloid nucleus (van Leeuwen and 
Caffe, 1983). Each discrete region plays a different 
physiological role through the three different vaso-
pressin receptors, such as V1a (Morel et al. 1992), 
V1b (Sugimoto et al. 1994), and V2 (Lolait et al. 
1992) receptor. In the peripheral tissues, the vaso-
pressin gene expression is detected in the thymus, 
testis and vasculature.
Compared with vasopressin, CRH is more 
extensively distributed in many brain areas, the 
spinal cord and peripheral tissues (Cummings et al. 
1983; Keegan et al. 1994). In the hypothalamus, 
CRH-positive neurons are mainly recognized in 
the parvocellular subdivision of PVN, some of 
which are co-localized with vasopressin. In con-
trast, there are few CRH-positive fibers in the 
magnocellular subdivision of PVN and SON, 
where vasopressin is strongly expressed (Itoi et al. 
2004). The CRH gene expression is also observed 
in the cerebral cortex, limbic system (amygdala, 
hyppocampus, and BNST), thalamus, cerebellum, 
brainstem, and dorsal root of the spinal cord. In 
the periphery, CRH is present in the adrenal 
medulla (Hashimoto et al. 1984), gastrointestinal 
tract (Nieuwenhuijzen Kruseman et al. 1982), skin 
(Slominski et al. 1998), and placenta (Petraglia 
et al. 1987); most of these organs are deeply asso-
ciated with stress or immune responses.
The physiological effect of CRH and related 
peptides such as Ucns is exerted via CRH recep-
tors, which belong to the seven-transmembrane, 
G-protein coupled receptors (GPCR). To date, two 
subtypes of CRH receptor, CRHR1 (Chen et al. 
1993) and CRHR2 (Lovenberg et al. 1995) have 
been identified. They have approximately 70% 
similarity at the amino acid level. In addition, eight 
splice variants of CRHR1 (a-h isoforms) (Pisarchik 
and Slominski, 2001) and three splice variants of 
CRHR2 (α, β and γ isoforms) (Catalano et al. 
2003) have already been characterized. CRHR1 is 
distributed throughout the brain, in areas such as 
the cerebral cortex, cerebellum, olfactory bulb, 
hippocampus, amygdala, and more importantly, 
anterior pituitary corticotroph. CRHR2α expres-
sion is restricted to the brain, in areas such as the 
hypothalamus, lateral septum, and hippocampus, 
whereas CRH-R2β is widely expressed in the 
peripheral tissues, including the heart, lung, gas-
trointestinal tract, and skeletal muscle. In contrast, 
CRHR2γ is only detected in the human brain. CRH 
mainly binds CRHR1, but not CRHR2. On the 
other hand, all Ucns bind CRHR2 with high affin-
ity. Ucn1 have equal affinities for CRHR1 and 
CRHR2; however, neither Ucn2 nor Ucn3 binds 
CRHR1. The above observation suggests that each 
of the CRH and Ucns exerts different physiologi-
cal functions in the different target tissues via these 
receptors.
In the systemic circulation, CRH and Ucn1 are 
known to bind CRH-binding protein (CRH-BP), 
resulting in the inactivation of CRH and Ucn1 
(Potter et al. 1991). In contrast, Ucn2 and Ucn3 
cannot form the dimer complex with CRH-BP. The 
mRNA of CRH-BP is detected in the cerebral 
cortex, limbic systems including amygdala, brain-
stem, and pituitary corticotroph (Potter et al. 1992). 
In addition, CRH-BP is also expressed in the pla-
centa (Petraglia et al. 1993). CRH-BP blocks the 
inappropriate activation of the HPA axis in preg-
nant women, because circulating CRH derived 
from placenta progressively increases during preg-
nancy (Sasaki et al. 1984). In CRH-BP transgenic 
animals, the plasma concentration of ACTH and 
corticosterone is not reduced, despite the abundant 
expression of CRH-BP in the pituitary (Burrows 
et al. 1998). CRH and vasopressin mRNA in PVN 
is elevated in these mice, suggesting that they 
compensate for the deteriorated function of CRH 
in corticotroph and resultantly maintain the 
HPA axis.
Physiological Roles
Potent antidiuresis is the most important physio-
logical role of vasopressin. Vasopressin achieves 
the prevention of body fluid loss by regulating the 
reabsorption of water in the kidney. Therefore, 
vasopressin deficiency causes central diabetes 
insipidus (CDI) with marked polyuria at an amount 
of more than 10 liters per day. In the magnocel-
lular neurons of SON and PVN, the vasopressin 
synthesis is stringently mediated by the plasma 
osmolality (Robertson et al. 1976). The magnocel-
lular neurons perceive the osmotic stimuli through 
the excitatory glutaminergic and inhibitory GAB-
Aergic neurons projected from the osmoreceptors. 
The osmoreceptor is a unique osmosensitive organ, 74
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located in the circumventricular region which 
includes the subfornical organ (SFO), organum 
vasculosum of the lamina terminalis (OVLT), and 
median preoptic nuclei (MnPO) (Andersson, 1977; 
Bourque and Oliet, 1997; Burbach et al. 2001; 
McKinley et al. 2004). Vasopressin is packaged 
within the secretory granules and transported into 
the nerve terminals of the magnocellular neurons. 
Vasopressin is first gathered in the posterior pitu-
itary and then rapidly released into the general 
circulation in response to hyperosmotic change. In 
contrast, it is also presumed that the magnocellular 
neurons are themselves osmosensitive, because the 
osmotic change electrically evokes these vaso-
pressinergic neurons (Mason, 1980; Oliet and 
Bourque, 1993; Zhang and Bourque, 2003). Unfor-
tunately, the precise mechanism of the direct 
osmosensitivity of the magnocellular neurons has 
been unexplored, partly because isolated pure 
vasopressinergic neurons are not readily available.
The antidiuretic effect of vasopressin is 
achieved through the GPCR member, V2 recep-
tor (V2R), which is expressed at the basolateral 
side of the tubules and the collecting ducts of the 
kidney (Lolait et al. 1992; Knepper, 1997; 
Robben et al. 2006). A rapid accumulation of the 
intracellular cAMP and the subsequent activation 
of protein kinase A (PKA) is observed, after 
vasopressin in the circulation binds V2R. 
Afterwards, a water channel, aquaporine2 
(AQP2), which is present in the intracellular 
vesicles, is rapidly phosphorylated at the portion 
of Ser256 through the cAMP/PKA-dependent 
pathway (Fushimi et al. 1993; Kuwahara et al. 
1995). The activated AQP2 migrates to the apical 
membrane of the principle cells of the collecting 
ducts. A large amount of water is reabsorbed 
through AQP2 and returned into the circulation 
through AQP3 and AQP4, present in the opposite 
basolateral site of these cells. Finally, AQP2 is 
dephosphorylated and internalized to the original 
stores in the cytoplasm. This sophisticated recy-
cling system of AQP2 regulates the water balance 
in the body.
Vasopressin also maintains the cardiovascular 
system in response to hemodynamic stress 
(Johnston, 1985; Arnolda et al. 1986). Hypotension 
or hypovolemia initiates the secretion of vasopressin 
from the posterior pituitary through the baroreceptor 
in the aortic arch and chemoreceptor in the carotid 
body. In fact, the name “vasopressin” comes from 
the vasopressor action. Vasopressin increases the 
arterial blood pressure through the V1a receptor 
(V1aR), which exists in the vessel wall (Morel 
et al. 1992; Koshimizu et al. 2006). Clinically, 
vasopressin is recently being used as a potent 
hypertensive drug, as are cathecholamines, for the 
rescue of patients in shock in the emergency room 
(Wenzel and Lindner, 2006). In addition, the V1aR 
gene expression is also observed in many brain 
areas, where vasopressin promotes social behavior, 
learning and memory (Everts and Koolhaas, 1999; 
Bielsky et al. 2004). Vasopressin causes aggression 
or paternal behavior through the brain V1aR, in 
contrast to oxytocin, which causes maternal 
behavior (Bielsky and Young, 2004). Otherwise, 
several vasopressin derivatives which enhance 
the memory retention have been developed 
(Hirate et al. 1997).
Interestingly, there are some common physio-
logical actions in vasopressin and CRH, even 
though their molecular structure do not resemble 
each other. Vasopressin and CRH are deeply asso-
ciated with the neuroimmunomodulation system, 
because they activate the HPA axis playing a prin-
cipal role in stress and immune response (Aguilera, 
1994; Turnbull and Rivier, 1999). CRH and vaso-
pressin act as ACTH secretagogues (DeBold et al. 
1984; Rivier et al. 1984; Antoni, 1993). In PVN, 
the parvocellular neurons expressing CRH and 
vasopressin extend to the corticotroph cells in the 
anterior pituitary through the median eminence 
(Holmes et al. 1986). CRH promotes the rapid 
release of ACTH from the corticotroph via the 
CRHR1. Then, ACTH stimulates the glucocorti-
coid synthesis and secretion from the adrenal 
cortex. In addition, CRH is also capable of stimu-
lating the adrenal gland directly and inducing 
glucocorticoid production. Almost all CRH-
positive neurons do not express vasopressin in the 
basal condition; however, a number of these 
neurons start to express vasopressin after receiving 
the stress, resulting in the increase of the ACTH 
secretion via the corticotroph V1b receptor (V1bR), 
as is the case with CRH. Compared with CRH, 
vasopressin itself has a weak ability of up-
regulating the ACTH secretion; however, it 
markedly potentiates the effect of CRH (Gilles 
et al. 1982; DeBold et al. 1984; Volpi et al. 2004). 
Altogether, CRH and vasopressin are characterized 
as upstream regulators of the HPA axis.
The synthesis and secretion of hypothalamic 
CRH and vasopressin, in turn, receive negative 
feedback by the excessive production of glucocorticoid. 75
Gene regulation system of vasopressin and corticotoropin-releasing hormone
Gene Regulation and Systems Biology 2008:2 
There is abundant evidence regarding the 
suppression of CRH and vasopressin gene expres-
sion by glucocorticoid. Adrenalectomy induces the 
CRH mRNA expression in the PVN; however, the 
CRH gene expression was decreased by glucocor-
ticoid replacement (Jingami et al. 1985; Bayer 
et al. 1988). On the other hand, CRH heteronuclear 
(hn) RNA and mRNA expression are significantly 
decreased in adrenalectomized rats, after stress 
stimulation (Tanimura and Watts, 1998). The latter 
interesting observation suggests that a physiolog-
ical concentration of glucocorticoid is important 
for the stress-induced CRH expression. It is 
strongly assumed that the glucocorticoid receptor 
(GR), which is expressed in PVN and pituitary 
corticotroph, is involved in this negative feedback 
system. In SON, the GR expression is undetectable 
under normal conditions, but it becomes recogniz-
able under chronically hypoosmotic stimulation 
(Berghorn et al. 1995). Interestingly, the CRH 
production is up-regulated by glucocorticoid in 
other tissues such as the amygdala (Makino et al. 
1994a), BNST (Makino et al. 1994b) and placenta 
(Robinson et al. 1988). Aside from this, other 
investigators report that the CRH gene expression 
in the amygdala is unchangeable by glucocorticoid 
(Kasckow et al. 1997). In any case, the precise 
mechanisms of these tissue-specific regulations of 
CRH gene expression by glucocorticoid have not 
been fully elucidated.
After adrenalectomy, vasopressin immunoreac-
tivity is markedly elevated in the CRH-positive, 
parvocellular neurons in PVN (Sawchenko et al. 
1984; Kiss et al. 1984). A significant increase in 
the basal and stress-induced vasopressin mRNA 
value in the parvocellular, but not the adjacent 
magnocellular division of PVN, is observed in 
adrenalectomized rats, whereas it returns to the 
basal level after glucocorticoid administration 
(Kovacs et al. 2000). In the human, it is assumed 
that hyponatremia followed by adrenal insuffi-
ciency is mainly due to the excessive production 
of vasopressin. In hypothalamic organotypic slice 
culture, it has been confirmed that dexamethasone 
treatment significantly suppresses the vasopressin 
gene mRNA in PVN, but not SCN (Kuwahara et al. 
2003.) This ex vivo study also indicates that the 
suppressive effect on the cAMP-induced transcrip-
tion activity by dexamethasone occurs in the 
vasopressinergic neurons themselves, indepen-
dently of the synaptic interaction with the projected 
neurons.
It is ordinarily expected that the lack of CRH 
results in blunted or absent ACTH secretion. Inter-
estingly, no significant difference of plasma ACTH 
concentration is observed under the basal condition 
between CRH-knockout and wild-type mice 
(Muglia et al. 1995). The mRNA expression of 
proopiomelanocortin (POMC), which is a large 
precursor of ACTH, is not impaired in corticotroph 
of CRH KO mice. Pituitary histology of knockout 
mice appears normal. On the other hand, the 
decrease of pituitary ACTH contents is approxi-
mately 70% of those of wild-type, probably reflect-
ing the slight depletion of ACTH stores in 
corticotroph (Muglia et al. 2000). These observa-
tion suggest that CRH is not necessarily required 
for the basal expression of ACTH. Furthermore, 
vasopressin does not contribute to maintain the 
POMC gene expression in CRH deficiency, 
because the increase of the vasopressin immuno-
reactivity is unrecognized in PVN (Muglia et al. 
1995). It is of interest that the gel filtration analy-
sis shows that the unprocessed large precursor of 
ACTH accounts for a high percentage of immuno-
reactive ACTH in the anterior pituitary in CRH 
KO mice, probably because CRH serves as an 
activator of processing enzymes such as prohor-
mone convertase 1/3 (PC1/3) which produces the 
authentic-sized, bioactive ACTH (Muglia et al. 
2000; Fukuda et al. 2004). Unlike basal ACTH 
secretion, the stimulatory effect of plasma ACTH 
in CRH KO is smaller than that in wild-type, after 
pain stress. This result indicates that CRH plays 
an indispensable role in the induction of the ACTH 
release, especially under the stress condition.
The plasma corticosterone level in CRH-
deficient mice is significantly lower in comparison 
to wild-type animals (Muglia et al. 1995). 
Moreover, severe atrophy of the zona fasciculata 
of the adrenal cortex where corticosterone is 
produced is observed in male CRH knockout mice. 
In female knockout mice, the extent of this 
hypoplasia is less than that of male knockout mice. 
On the other hand, the zona glomerulosa, where 
mineralocorticoid is mainly produced, and the 
adrenal medulla are histologically normal. After 
restraint stress followed by ether exposure, lower 
plasma corticosterone level of CRH-deficient mice 
is observed, compared with the wild-type. In par-
ticular, male knockout mice exhibit an extremely 
impaired ability to secrete corticosterone. The 
plasma corticosterone remains at the minimal level 
at the circadian nadir in normal rodents. This gender 76
Yoshida
Gene Regulation and Systems Biology 2008:2 
difference of adrenal responsiveness may be caused 
by the effect of sex hormones on the HPA axis. In 
addition, despite hypoglycemia by food depriva-
tion, corticosterone concentration is not elevated 
in knockout mice. Altogether, the stress response 
is markedly reduced in CRH KO mice. In addition 
to the atrophy of the zona fasciculata, it is possible 
that the increase of unprocessed ACTH precursor 
affects the corticosterone production to some 
extent.
From a different viewpoint, it is an unexpected 
observation that basal ACTH is not elevated at all 
in male CRH KO mice despite adrenal insuffi-
ciency, because their corticosterone level is low. 
Likewise, no elevation of basal circulating ACTH 
is observed in the adrenalectomized CRH-deficient 
mice. Notably, exogenous CRH injection rapidly 
induces the ACTH secretion in these adrenalecto-
mized mice, suggesting that CRH is essential to 
the ACTH secretion rather than the POMC gene 
transcription. Alternatively, the expression of 
CRHR1 in corticotroph may be significantly 
up-regulated in the CRH deficiency.
The expression of the vasopressin and CRH 
gene in the PVN parvocellular neurons is induced 
by the pro-inflammatory cytokines. There are 
several reports regarding the interaction between 
CRH/vasopressin and cytokines by the directly 
peripheral or cerebral administration of cytokines 
in vivo, or the ex vivo hypothalamic culture system. 
It is well-known that an excessive production of 
vasopressin induces the “syndrome of inappropri-
ate secretion of antidiuretic hormone (SIADH),” 
which is characterized by hyponatoremia with 
excessive sodium excretion from the kidney 
(Bartter and Schwartz, 1967; Robertson, 2006; 
Ellison and Berl, 2007). Indeed, interleukin-6 
(IL-6) leads to the excessive production of vaso-
pressin in the hypothalamus in patients with 
meningitis or encephalitis, often causing SIADH 
(Baylis, 2003). In the dissociated fetal hypothalamic 
cell culture derived from the Fisher (F344/N) rat, 
24h exposure of IL-6 stimulates vasopressin release 
(Wei et al. 2002). In this paper, IL-1β, TNFα, and 
lipopolysaccharide also increase the vasopressin 
secretion in a dose-dependent manner. In humans, 
plasma vasopressin levels are elevated 2h after 
IL-6 injection (Mastorakos et al. 1994). Interest-
ingly, a recent analysis using DNA microarray 
shows a robust expression of IL-6 in rat SON after 
a 48h water deprivation (Ghorbel et al. 2003). The 
authors confirmed the coexistence of vasopressin 
and IL-6 in SON of the dehydrated rat, suggesting 
that IL-6 promotes the induction of the vasopressin 
expression and/or secretion through the autocrine/
paracrine system. Consistent with the above find-
ings, most of the vasopressin-positive cells in PVN 
and SON are co-localized with IL-6, whereas the 
expression pattern of the CRH-positive cells 
depends on the type of cells (Gonzalez-Hernandez 
et al. 2006).
It is also known that exposure to cytokines 
augments the expression and/or secretion of CRH. 
Infusions of IL-1 induced a significant secretion 
of hypothalamic CRH (Sapolsky et al. 1987; 
Berkenbosch et al. 1987). The intraperitoneal 
injection of IL-1α/β stimulates hypothalamic CRH 
mRNA expression and release (Suda et al. 1990). 
IL-1β increases CRH secretion from dispersed 
fetal rat hypothalamic cells, whereas this stimula-
tory effect is abolished by the treatment of protein 
kinase A (PKA) and protein kinase C (PKC) 
inhibitor (Hu et al. 1992a). Also, the endogenous 
CRH mRNA expression is induced by IL-1β along 
with the induction of c-fos, c-jun, and GR gene 
expression in human hepatoma NPLC-KC cells 
(Gill et al. 1998). On the other hand, IL-6 also 
increases the CRH gene expression in hypotha-
lamic explants (Lyson and McCann, 1993), 
dissociated amygdalar cultures (Kasckow et al. 
1997), and human endometrial cells (Makrigiannakis 
et al. 1999). IL-6, IL-1β and TNFα stimulate CRH 
secretion in dissociated hypothalamic culture 
(Wei et al. 2002). Thus, these observation indicate 
that the administration of IL-1α/β, IL-6 and other 
cytokines can promote the induction of the tran-
scription and/or secretion of CRH/vasopressin in 
vivo. However, it is unclear whether these cyto-
kines directly stimulate the PVN neurons, or 
indirectly stimulate them through the afferent 
neuronal inputs from other neurons, after perceiv-
ing the stimuli of these cytokines. Notably, the 
expression of cytokines in the brain is activated 
not only by inflammation, but also by a wide 
variety of stresses such as dehydration, restraint, 
swimming, or emotions. These cytokines may 
have a pleiotropic effect over the immune 
response. The peripheral administration of IL-
1α/β induces plasma IL-6, suggesting that there 
exist complicated signaling cascades between the 
cytokines (Libert et al. 1990). Thus, brain cyto-
kines have the ability to carry the various kinds 
of stress signals in the central nervous system, like 
hormones or neurotransmitters. For example, the 77
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following interesting observations regarding the 
relationship between IL-6 and the HPA axis using 
CRH-deficient mice have been reported (Bethin 
et al. 2000). After IL-6 injection, plasma ACTH 
increases in wild-type mice; however, a greater 
increase of ACTH is observed in CRH KO mice. 
The authors confirmed the expression of IL-6 
receptor in the pituitary corticotroph and adrenal 
cortex. After lipopolysaccharide injection, the 
plasma corticosterone level is lower in either CRH 
or IL-6 knockout mice than in the wild-type; how-
ever, this stimulatory effect is almost unrecognized 
in CRH and IL-6 double knockout mice. These 
serial results indicate that IL-6 up-regulates the 
activation of the HPA axis alternative to CRH. 
Thus, IL-6 activates the HPA axis through a CRH-
dependent pathway and an independent pathway. 
All together, the profound relationship between 
vasopressin/CRH and cytokines develops the 
immune-endocrine cross-talk system, supporting 
not only the immune response, but also wide-
ranged, life-saving reactions to life-threatening 
environmental changes.
Molecular Mechanisms
of Vasopressin and CRH Gene 
Transcription
The vasopressin and CRH gene expression is 
activated by numerous physiological stimuli, as 
described above. Because the roles of these 
hormones are closely linked to life homeostasis, it 
becomes necessary to establish an accurate and 
stringent gene regulation system. For example, 
clinically, excessive production of vasopressin is 
known to cause SIADH, whereas excessive CRH 
causes Cushing disease, depression, and anorexia 
nervosa. To understand the gene expression of both 
neuropeptides, numerous detailed promoter 
analyses have been carried out. Several important 
cis-elements in the 5’-promoter region and 
intracellular signaling cascades have been 
identified (Fig. 1 and 2).
cAMP/PKA
It is generally accepted that cAMP is an important 
positive inducer of the vasopressin gene transcription. 
There is much evidence that the cAMP/PKA 
activation leads to the immediate induction of the 
vasopressin gene expression. The marked elevation 
of the intracellular cAMP is observed in SON 
during a hyperosmotic stimulation (Carter and 
Murphy, 1989). The phospholylation of CRE-binding 
protein (CREB) is rapidly induced in SON after 
osmotic stimulus (Shiromani et al. 1995). In 
addition, the cAMP activator elevates the vasopressin 
gene expression in fetal hypothalamic culture (Hu 
et al. 1993) and dissociated hypothalamic primary 
culture (Wei et al. 2002). Precise reporter analyses 
using the heterologous cell lines show that cAMP 
stimulator also augments vasopressin gene 
transcription (Pardy et al. 1992; Emanuel et al. 
1992). Two CREs have been identified in the rat 
vasopressin 5’-promoter region (-227/-220 and 
-123/-116) using placenta-derived JEG3 cells 
(Iwasaki et al. 1997). In this paper, co-transfection 
with the PKA catalytic subunit (a constitutive active 
form of PKA) or CREB expression vector 
significantly induces the vasopressin gene promoter 
activity, as well as cAMP stimulators. However, the 
direct binding of CREB proteins to these putative 
CREs has not been verified by electrophoretic 
mobility shift assay (EMSA) or chromatin 
immunoprecipitation (ChIP).
It is known that the activation of CREB is medi-
ated by Ca-dependent pathway, as well as a cAMP/
PKA signaling pathway. Calcium/calmodulin-
dependent protein kinase (CaMK) II activates the 
CREB proteins through phosphorylation at the 
portion of Ser133 (Sheng et al. 1991; Dash et al. 
1991). However, to date, there is no report that the 
Ca influx induces the vasopressin gene promoter 
activity.
The CRH gene promoter activity is also 
enhanced through the cAMP/PKA-dependent 
pathway. The CRH gene expression and release 
are activated by the cAMP/PKA-dependent path-
way using hypothalamic explants (Suda et al. 
1990). The activation of the PKA signaling also 
increases the CRH gene expression in rat fetal 
hypothalamic cultures (Emanuel et al. 1992), or 
primary amygdalar cultures (Kasckow et al. 1997). 
Moreover, cAMP activator stimulates the endog-
enous CRH mRNA expression and secretes CRH 
in culture medium in homologous BE(2)M17 
(Kasckow et al. 1994) and BE(2)C cell lines 
(Kasckow et al. 1995). The gene expression of 
endogenous CRH is also up-regulated in the 
immortalized hypothalamic (Nikodemova et al. 
2003) and amygdalar (Mulchahey et al. 1999) cell 
lines.
An important CRE site has been identified in 
the human CRH promoter region (-228/-221), 78
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Figure 1. Proposed model of the molecular mechanisms of the vasopressin gene transcription.
A variety of transcription factors and signaling pathways are involved in the transcriptional regulation of the vasopressin gene. In the 
homologous vasopressinergic neurons in the hypothalamus, cAMP acts as an important second messenger of the vasopressin gene activa-
tion. After receiving the stresses, the activation of the cAMP/PKA pathways promotes the phosphorylation of CREB. This phosphorylated 
CREB activates the vasopressin promoter activity through the CRE site. The immediate early genes, Fos/Jun family proteins, also induce 
the vasopressin gene transcription by direct binding to the AP1 element, in response to various kinds of stimuli. In SCN, the Clock and Bmal1 
heterodimer generates the circadian regulation of the vasopressin gene via the E-box element. On the other hand, REST/NRSF represses 
the vasopressin promoter activity via the RE-1/NRSE site in the heterologous cells. In contrast, in some cancer cells, such as small cell lung 
carcinoma (SCLC), the splice variant of REST/NRSF and/or USF1/USF2 induces the ectopic expression of the vasopressin gene.
using neuroblastoma SK-N-MC and choriocar-
cinoma JAR cell lines (Spengler et al. 1992). 
The cAMP-induced CRH promoter activity is 
reduced in the deletion construct which does not 
contain CRE. When only single or multiple cop-
ies of this CRE (-228/-221) were fused to tk 
promoter, forskolin treatment also induced the 
transcription activity of these heterologous pro-
moters. The sequence of CRE in the CRH pro-
moter, TGACGTCA, is completely matched to 
the consensus CRE. In addition, a novel cAMP-
responsive element, caudal-type homeobox 
response element (CDXRE), has also been found 
in the proximal promoter region of CRH (-125/-
118) (King et al. 2002). According to this paper, 
the cAMP-stimulating effect of the CRH pro-
moter activity is not abolished in the mutated 
construct in which only CRE is disrupted in 
AtT20 cells. It is possible that both CRE and 
CDXRE participate in the cAMP-mediated CRH 
gene promoter activity.
AP1/ PKC
In contrast to the cAMP-mediated pathway, the 
role of the Fos/Jun family proteins in the vasopres-
sin gene regulation is still obscure. Recently, our 
group identified a functional activation protein 1 
(AP1) element (-134/-128, TGAATCA) in the rat 
vasopressin promoter using human neuroblastoma 
BE(2)M17 cells (Yoshida et al. 2006). The AP1 
protein consists of five Fos proteins (c-Fos, Fra-1, 
Fra-2, FosB, and its natural truncated form ∆FosB), 
and three Jun proteins (c-Jun, JunB, and JunD) 
(Herdegen and Waetzig, 2001). The Fos/Jun fam-
ily of proteins is known as an immediate early gene 
in neuronal cells, because the expression is induced 
rapidly in response to diverse extracellular stimuli. 79
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Figure 2. Proposed model of the molecular mechanisms of the CRH gene transcription.
A variety of transcription factors and signaling pathways are involved in the transcriptional regulation of the CRH gene. The cAMP/PKA 
signaling cascade acts as an important second messenger of the CRH gene activation. The promoter activity of the CRH gene is induced 
by the phosphorylated CREB via the CRE site. The CDXRE region is also thought to be a responsible site. It is possible that the Fos/Jun 
family proteins activate the CRH gene transcription in response to various kinds of stimuli via the putative AP1 site. In addition, in PVN, CRH 
gene promoter activity is negatively regulated by GR, which directly binds to nGRE and/or interacts with another nuclear factor on CRE. In 
the latter case, SRC-1a is a candidate protein which supports this suppressive effect of GR. On the other hand, in the heterologous cells, 
REST/NRSF inhibits the random expression of the CRH gene as a silencing factor.
For example, c-Fos is widely used as a stress 
marker in neurons. These proteins bind to a specific 
sequence (TGAC/GTCA; known as AP1) of the 
promoter region of the target genes, by forming a 
homodimer (Jun/Jun) or heterodimer (Fos/Jun). 
Indeed, the Fos/Jun family proteins mediate the 
stress-induced transcription activity of many 
genes in the endocrine system, including ACTH 
(Boutillier et al. 1995), prolactin (Caccavelli et al. 
1998), and follicle-stimulating hormone (FSH) 
(Strahl et al. 1997).
Many previous studies have shown that the 
Fos/Jun family proteins are rapidly expressed in 
the vasopressinergic neurons in response to a vari-
ety of extracellular stimuli, synchronizing with the 
activation of vasopressin gene expression. Accord-
ing to the type of stress, such as hypertonic saline 
(Sharp et al. 1991; Shiromani et al. 1995; Carter 
and Murphy, 1990), lipopolysaccharide (Rivest 
and Laflamme, 1995; Xu et al. 2003), or photic 
stimulation (Francois-Bellan et al. 1999), differ-
ential expression patterns (both spatial and 
temporal) of Fos/Jun family proteins are observed. 
In the vasopressinergic neurons in the SON and 
PVN, the acute osmotic stimuli increase c-fos, 
c-jun, and junB mRNAs (Luckman et al. 1996). 
Sustained expression of Fos family proteins was 
also reported during chronic hypertonic saline 
treatment (Miyata et al. 2001). These results 
strongly suggest that the Fos/Jun family proteins 
mediate the rapid transcriptional induction of the 
vasopressin gene by extracellular stimuli. The AP1 
site we identified is the sole responsible element 
for Fos/Jun proteins, because the AP1-induced 
potent transcription activity of the vasopressin gene 
is completely abolished when the AP1 site is 
altered. The expression pattern of each Fos or Jun 
protein is different, depending on the type of stress. 
The homodimers or heterodimers of Fos/Jun pro-
teins bind to the AP1 site with different affinities 
(Nakabeppu et al. 1988). Therefore, various kinds 
of stress may lead to the generation of the divergent 
and complicated regulation pattern of vasopressin 
gene expression via the AP1 proteins.80
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The involvement of the protein kinase C (PKC) 
pathway in the vasopressin gene promoter activity 
still remains unclear (Hu et al. 1992b; Hu et al. 
1993; Wayte et al. 1997; Wei et al. 2002; Arima 
et al. 2003). However, because the activation of 
the Fos/Jun family proteins is deeply associated 
with the PKC pathway, we hypothesized that the 
activation of PKC increases the vasopressin gene 
promoter activity through the c-Fos-mediated 
pathway. Our group showed the possibility of this 
hypothesis using BE(2)M17 cells (Yoshida et al. 
2006). A PKC activator, 12-O-tetradecanoyl phor-
bor 13-acetate (TPA), increased the vasopressin 
gene promoter activity. This stimulatory effect is 
significantly decreased by the elimination of the 
AP1 site, or blocked by the treatment of the specific 
extracellular signal-regulated kinase (ERK) inhib-
itor, or PKC inhibitor. The promoter region of the 
c-fos gene contains the serum response element 
(SRE), the sis-inducible element (SIE), and CRE 
(Treisman, 1995). The c-fos gene expression can 
be induced rapidly by a wide variety of extracel-
lular stimuli through these cis-regulatory elements 
(Jacknecht, 1995). In particular, the SRE element 
is an important region of the PKC-induced 
transcription of the c-fos gene, mediated by the 
activation of the ERK signaling cascade. Our result 
implies that the vasopressin gene promoter activity 
is enhanced through the activation of the PKC-
ERK-c-Fos signaling pathway.
The role of the PKC pathway or AP1 proteins 
in CRH gene regulation is still controversial. TPA 
stimulates the CRH gene expression in heterolo-
gous NPLC cells through the elongation of the 
additional poly (A) tail (Adler et al. 1992). TPA, 
as well as Fsk increases the CRH secretion from 
hepatoma-derived, homologous NPLC-KC cells 
(Parkes et al. 1993), or from dissociated hypo-
thalamic primary culture (Wei et al. 2002). Other 
studies have shown that microinjected TPA does 
not significantly enhance the CRH mRNA value 
(Itoi et al. 1996). As with vasopressin, the Fos/
Jun family proteins are rapidly expressed in the 
CRH neurons in response to a variety of extracel-
lular stimuli, suggesting that AP1 proteins acti-
vate the CRH gene expression. The co-expression 
of c-fos or c-jun increases the promoter activity 
of CRH gene via two putative AP1 elements in 
the 5’-flanking region of the CRH gene (Malkoski 
and Dorin, 1999) (see below). On the other hand, 
pre-treatment of c-fos antisense oligonucleotide 
fails to suppress the hypoglycemia-induced CRH 
gene expression in the hypothalamus (Itoi 
et al. 1996).
Glucocorticoid
GR up-regulates the transcription activity of many 
target genes at the glucocorticoid response element 
(GRE), consensus GGTACANNNTGTTCT 
(Lieberman, 2007). Many investigators have made 
efforts to clarify the molecular mechanism of the 
negative regulation by glucocorticoid in the vaso-
pressin or CRH gene transcription. To explain the 
negative feedback system, two hypotheses have 
been advocated: 1) GR dimer suppresses the pro-
moter activity by directly binding to the so-called 
negative GRE (nGRE). 2) The interaction between 
GR and other transcriptional factors or cofactors 
inhibits the binding of these nuclear factors to the 
specific cis-acting element. In fact, the promoter 
sequences of many genes whose expression is 
negatively regulated by glucocorticoid, does not 
always contain GRE or nGRE. In the majority of 
these genes, GR can attenuate the promoter activity 
by a squelching or tethering effect to other factors 
without binding directly to GRE. Putative GRE was 
pointed out in -622/-608 of the rat vasopressin 
promoter region (Mohr and Richter, 1990). How-
ever, there have been various opinions regarding 
the suppressive element by glucocorticoid in the 
vasopressin gene. Putative GRE is located within 
the region -300 to -155 in the bovine vasopressin 
promoter sequence by EMSA (Burke et al. 1997). 
On the other hand, in the deletion analysis using 
placenta-derived JEG3 cells, the responsive ele-
ment for the suppressive effect by dexamethasone 
on the cAMP-induced promoter activity is present 
in -102 to -36 of the rat vasopressin promoter region 
(Iwasaki et al. 1997). This suppressive effect still 
remains in the mutated construct in which two puta-
tive CREs are eliminated, suggesting that gluco-
corticoid reduces the vasopressin promoter activity 
independently of CREs. Otherwise, putative GRE 
is -628 in the vasopressin gene promoter region 
(Kim et al. 2001). The vasopressin gene promoter 
activity is suppressed through this element, after 
dexamethasone treatment.
Only the 18bp CRE-containing region (-232/-
215) serves as a responsive site for the suppressive 
effect by glucocorticoid on the cAMP-induced 
human CRH gene promoter activity in corticotroph 
AtT20 cells (Guardiola-Diaz et al. 1996). On the 
contrary, functional negative (n) GRE sites are 81
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identified in the 5′-flanking region (-278/-249) 
of the CRH gene (Malkoski and Dorin, 1999). 
Three serial GRE half-sites are recognized in the 
above short sequences, all of which are involved in 
the negative regulation of the CRH gene transcrip-
tion by the direct binding of GR. 8-bromo cAMP-
induced CRH gene promoter activity is significantly 
reduced by glucocorticoid in AtT20 cells; however, 
this suppressive effect is abolished in the deleted 
or mutated construct lacking these nGRE site(s). 
According to this paper, two AP1 sites are located 
adjacent to the GRE half-sites. The c-Fos- or c-Jun-
induced promoter activity of the CRH gene is 
significantly repressed by dexamethasone treat-
ment, probably due to the close proximity of AP1-
like sites and GREs (partly overlapping). On the 
other hand, this repressive effect is exerted by the 
interaction between nGRE and CRE (King et al. 
2002). As expected, this effect is abolished in the 
deletion construct which contains CRE, but not 
nGRE, whereas this effect is also lost in the mutated 
construct in which only CRE (-228/-221) is altered. 
In addition, glucocorticoid stimulates the transcrip-
tion activity in the minimal homologous or heter-
ologous promoter, which is constructed by the 
insertion of the isolated CRE. These observation 
suggests that CRE serves as a main responsive site 
for the inhibitory effect by glucocorticoid in the 
presence of nGRE. EMSA analysis shows that 
CREB and c-Fos can bind CRE in AtT20 cells, and 
that the binding ability of these nuclear factors is 
reduced by the treatment of dexamethasone together 
with cAMP, implying that negative regulation of 
the CRH gene is caused by the protein-protein 
interaction between CREB, c-Fos, or other unknown 
factors and GR on the CRE site. There is another 
paper dealing with the importance of CRE in the 
negative regulation by glucocorticoid (Yamamori 
et al. 2007). The forskolin-stimulated CRH gene 
promoter activity is suppressed by dexamethasone 
in the BE(2)C cells which endogenously express 
CRH. This inhibitory effect is ablated by the 
elimination of CRE, but not nGREs.
There is an interesting report about the interac-
tion of GR and a coactivator in the CRH gene 
regulation by glucocorticoid (van der Laan et al. 
in press). According to this latest paper, when 
steroid receptor coactivator 1a (SRC-1a) is over-
expressed in AtT20 cells, the suppressive effect 
by dexamethasone on the Fsk-induced CRH gene 
promoter activity is enhanced, compared with the 
untransfected cells. Conversely, dexamethasone 
increases the Fsk-induced CRH gene promoter 
activity, when the SRC-1a isoform, SRC-1e, is 
introduced. The SRC family members are highly 
expressed in the brain and have a distinct expres-
sion pattern: SRC-1a mRNA is strongly expressed 
in the magnocellular and parvocellular parts of 
PVN and SON, whereas the expression level of 
SRC-1e mRNA is very high in the amygdala and 
much lower in PVN (Maijer et al. 2000). These 
observation suggest that the negative regulation 
of the CRH gene expression in PVN is mediated 
by SRC-1a. On the contrary, as mentioned above, 
the stimulating (or at least, nonsuppressible) effect 
on the CRH gene expression by glucocorticoid in 
the amygdala is probably due to the different 
expression pattern of SRCs. SRCs are known to 
act as a cofactor in cooperation with a variety of 
nuclear receptors or transcription factors (Xu and 
Li, 2003), such as AP1 (Lee et al. 1998) or nuclear 
factor kB (NFkB)(Na et al. 1998). Our group has 
also shown the preliminary data on the enhancing 
effect by SRC-1a on the vasopressin gene tran-
scription via AP1 site (Yoshida et al. 2006).
GR interacts with numerous transcription factors 
and intracellular signaling cascades, such as AP1, 
CREB, NFkB, NGFI-B/Nurr77, STAT family mem-
bers, and MAPKs, achieving the multipotential 
effect of glucocorticoid (Liberman et al. 2007). It is 
possible that GC reduces the CRH or vasopressin 
gene promoter activity, due to the inhibition of the 
activation of these transcription factors or signaling 
pathways at the transcriptional or posttranscriptional 
level. Otherwise, the acute non-genomic effect of 
glucocorticoid may support the rapid suppression of 
this hypothalamic hormone gene expression.
Circadian regulation
Vasopressin-positive fibers are observed in SCN, 
which is known to be a circadian generator. In 
SCN, the transcription of the vasopressin gene 
receives a unique circadian regulation by photic 
stimulation (Jin et al. 1999). This intrinsic circa-
dian oscillation of the vasopressin gene expression 
is still preserved in removed, organotypic slice 
cultures (Arima et al. 2002). The physiological 
significance of vasopressin in this region is unclear; 
however, it is possible that vasopressin in SCN 
influences the circadian rhythm of other brain 
peptides via synaptic interaction, as a pacemaker. 
In SCN, the heterodimer of Clock and Bmal1 
generates the circadian regulation of the vasopressin 82
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gene transcription via the CACGTG E-box element 
(Jin et al. 1999).
On the other hand, the CRH gene expression 
is undetectable in SCN. In contrast, the circadian 
regulation of the CRH mRNA expression is rec-
ognized in the mammalian PVN (Kwak et al. 
1992; Kwak et al. 1993). Therefore, the circadian 
variation of POMC gene expression in pituitary 
corticotroph is assumed to be derived from the 
circadian variation of CRH in PVN. This cyclic 
expression of CRH is not abolished in adrenalec-
tomized rats and it is preserved after the constitu-
tive replacement by the corticosterone pellet, 
indicating that circulating glucocorticoid is not 
involved in the circadian regulation of CRH 
(Watts et al. 2004). In addition, the circadian 
rhythm of plasma ACTH and corticosterone con-
centration becomes lost in male and female CRH 
KO mice (Muglia et al. 1997). However, constitu-
tive replacement of CRH (constant infusion by 
osmotic minipump) repairs the circadian variation 
of the HPA axis. This result suggests that the 
presence of CRH is required for the formation of 
the diurnal regulation of the HPA axis, but the 
circadian variation of CRH is not indispensable, 
at least in rodents. The circadian variation of the 
HPA axis may be generated by the cooperation of 
CRH and another circadian modulator, for exam-
ple, the neuronal inputs from SCN.
USF1/USF2
The vasopressin gene expression is limited to par-
ticular regions, even in the brain area. In contrast, 
in some cancer cells, such as small cell lung car-
cinoma (SCLC), the constitutive vasopressin gene 
expression is recognized and often causes SIADH. 
Unfortunately, the determinant of the tissue-
specific expression of the vasopressin gene has not 
been fully elucidated. Upstream stimulatory 
factor 1 (USF1) and USF2 contribute to the ectopic 
vasopressin gene expression in the SCLC cells, by 
the binding of the E-box element in the vasopres-
sin gene promoter region (Coulson et al. 1999a). 
USF1/USF2, which is a basic-helix-loop-helix 
(bHLH) transcription factor, is ubiquitously pres-
ent in a broad range of cells (Sirito et al. 1994). It 
preferentially binds to the E-box site and induces 
the promoter activity of target genes.
REST/NRSF
USF1/USF2 is not a determinant which facilitates 
the vasopressin gene expression in the SCLC cells 
in particular, and not other non-neuronal cells, 
because these transcription factors are ubiquitously 
expressed. To clarify the mechanism of the tissue-
specific gene expression, much more information 
about the epigenetic gene regulation system or 
silencing factors such as RNA interference is 
probably required. Epigenetic regulation is defined 
as the heritable change of gene expression without 
alteration in DNA sequence, including chromatin 
modification, such as DNA methylation or histone 
modification. Thus, the epigenetic modification 
serves as the first main switch of gene expression, 
and resultantly, various transcription factors serve 
as an activator or inactivator. For example, the 
methylation pattern of CpG sites in the genome is 
known to be a key determinant of the gene 
expression. It is known that the aberrant methylation 
of the CpG island of oncogenes is deeply involved 
in tumorigenesis. However, the understanding of 
epigenetics is also important to explain the 
mechanism of tissue-specific expression of many 
hormones.
Unfortunately, we have no information regarding 
the differences in methylation patterns of vasopressin 
and CRH gene between homologous and heterolo-
gous cells. However, recently, it is being assumed 
that an interesting silencing mechanism exists in 
both genes in non-neuronal cells. In the non-
neuronal cells, repressor element 1 (RE-1) silencing 
transcription factor/neuron-restrictive silencer fac-
tor (REST/NRSF) represses the vasopressin gene 
expression by the direct binding of a neuron-
restrictive silencer element (NRSE) (Ballas et al. 
2005). However, the splice variant of REST/NRSF, 
produced in several kinds of SCLC cells, interferes 
with the normal silencing function of wild-type 
REST/NRSF, facilitating the ectopic expression of 
the vasopressin gene in the heterologous cells 
(Coulson et al. 1999b). According to recent find-
ings, NRSF/REST represses the expression of many 
neuron-specific genes in non-neuronal cells, inter-
acting with histone deacetylases, mSin3, and CoR-
EST (Ballas and Mandel, 2005). The consensus 
NRSE motif (TTCAGCACCACGGAGCGCC) 
contains CpG dinucleotides which receive meth-
ylation in the differentiated non-neuronal cells, 
whereas the CpG island is poorly methylated in 
embryonic stem (ES) or neuron progenitor cells. It 
is possible that the differences in the methylation 
profiles of CpG sites in NRSE and its adjacent 
sequence are responsible for the gene silencing of 
the neuronal genes. In vasopressin gene expression, 83
Gene regulation system of vasopressin and corticotoropin-releasing hormone
Gene Regulation and Systems Biology 2008:2 
the epigenetic modification may also play an 
important role in the restricted expression.
The putative RE-1/NRSE site was previously 
predicted in the first intron of the CRH gene 
(Schoenherr et al. 1996). The sequence of this ele-
ment is highly conserved (90%−95%) among all 
species, in contrast to the lower similarity of CRH 
gene intron except RE-1/NRSE. When RE-1/NRSE 
is disrupted, the basal promoter activity of the CRH 
gene is robustly elevated in myoblast-derived L6 
cells in which REST/NRSF is abundantly expressed, 
compared with the wild-type construct (Seth and 
Majzoub, 2001). On the other hand, in neuronal 
PC12 cells, the promoter activity of the CRH gene 
is down-regulated by the overexpression of REST/
NRSF. The inhibitory effect by REST/NRSF is lost 
when RE-1/NRSE is mutated. Interestingly, the 
opposite observation is obtained in another neuro-
nal NG108 cell line. Thus, the promoter activity is 
stimulated in this mutant when REST/NRSF 
expression vector is introduced, indicating that 
REST/NRSF acts as an enhancer through the 
RE-1/NRSF-independent pathway, depending on 
the types of cells or tissues.
Perspective
As discussed above, vasopressin and CRH play a 
crucial role in the appropriate response to environ-
mental stimuli. Vasopressin and CRH possess 
diverse physiological functions, such as the main-
tenance of water balance and plasma osmolality, 
regulation of blood pressure, immune responses, 
energy homeostasis, feeding behavior, sexual 
behavior, emotion, and memory. They are thought 
to be fundamental and primitive reactions which 
have been conserved from comparatively lower 
organisms. These reactions can be divided into two 
groups: the static reaction such as the maintenance 
of equilibrium of the internal milieu, and the 
dynamic reaction such as active behavior to exter-
nal milieu. All of these are indispensable for the 
survival and existence for all organisms. Both 
hypothalamic neuropeptides conduct these basic 
responses to facilitate the flexible adjustment to 
the environmental changes.
Because the physiological action of vasopressin 
and CRH are directly linked to the maintenance of 
homeostasis, their gene expression must be medi-
ated stringently. The regulatory system is thought 
to be often highly conserved among species. Some 
important cis-elements have been discovered in the 
vasopressin and CRH gene promoter region. It is 
probably undeniable that the cAMP/PKA pathway 
activates the vasopressin and CRH gene transcrip-
tion, because of the large amount of evidence attest-
ing to it; however, the whole picture about other 
regulators has not yet been fully elucidated.
For example, there are still unsolved problems 
about the osmoregulatory system of the vasopres-
sin gene expression. Indeed, many investigators 
reveal the possibility that several transcription fac-
tors or signaling pathways are involved in osmo-
regulation. However, after the osmoreceptor (or 
vasopressinergic neuron itself?) perceives the 
osmotic stimuli, would only the above candidate 
members generate the osmotic induction of the 
vasopressin gene? Proteomics analysis may pro-
vide us with a satisfactory solution to this problem. 
Recently, several up-regulated and down-regulated 
genes were identified in SON by chronic dehydra-
tion using DNA microarray (Gouraud et al. 2007; 
Qui et al. 2007). Among these gene profiling lists, 
novel factors may be discovered, ones which 
stimulate the synthesis or secretion of vasopressin. 
It is also possible that the involvement of mRNA 
stability may be added to the previous detailed 
promoter analyses. Several investigators have 
shown that osmotic stress induces the elongation 
of the poly (A) tail of vasopressin mRNA, resulting 
in the mRNA stability which promotes the vaso-
pressin production (Carrazana, et al. 1988; Carter 
and Murphy, 1991).
There are different observations about the 
molecular mechanism of the negative feedback 
system by glucocorticoid, depending on the uti-
lized cell lines. To date, no consensus about this 
problem has been obtained. Most of the promoter 
analyses have been performed using the mono-
clonal culture cells, because the isolation of pure 
cells or neurons producing a particular hormone 
is extremely difficult. However, the observations 
made in tumor-derived cells are not always con-
sistent with one another. For example, it may 
pose as an obstacle that tumor-derived cell lines 
utilized in the promoter analysis often lack the 
endogenous GR.
Moreover, the divergent vasopressin and CRH 
gene expression implies the participation of an 
unknown regulation system, such as a non-coding 
RNA or silencing factor. What role does the 
untranslated long intron play in the gene regulation 
system? Research regarding this novel gene regu-
lation system has just begun. Tissue-specific 
expression of vasopressin and CRH may be under 84
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the epigenetic control. The methylation of the CpG 
island may possibly prevent the random ectopic 
expression of these genes. The osmosensitive fac-
tors may just be found among them. CRH was first 
discovered a quarter-century ago, and further, in 
the case of vasopressin, more than a half-century 
has already passed. Indeed, the progress in molec-
ular biology has extended our knowledge regarding 
these hormones; however, there are still many dif-
ficult problems that need to be solved.
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